PROVIDING AN EXECUTIVE PLATFORM TO FACILITATE THE SHARING OF GENOMIC AND PHENOTYPE DATA TO DRIVE CLINICAL PROGRESS

JOIN THE MOST EXCLUSIVE PRECISION MEDICINE SUMMIT IN THE HEART OF WASHINGTON DC

87% DIRECTOR LEVEL & ABOVE
175+ ATTENDEES
135+ ORGANIZATIONS
40+ EXPERT SPEAKERS

CONFIRMED PRECISION MEDICINE INNOVATORS INCLUDE:

Dr Cecilia Schott, VP Precision Medicine, Global Product & Portfolio, AstraZeneca
Mike Restuccia, SVP CIO, University of Pennsylvania Health System
Dr Teresa Zayas Caban, Director Scientist, Acting Chief of Staff, Office of the National Coordinator for Health Information Technology, US Department of Health and Human Services
Dr Jean-Claude Zenklusen, Director, Cancer Genome Atlas, National Cancer Institute, National Institute of Health
Dr Andrew Kernutsky, Head of Computational Biology, CRISPR Therapeutics

“Excellent speakers representing multiple stakeholders in creating and utilizing big data in precision medicine.”
Dr William Dalton, CEO, M2Gen

REGISTER NOW AT WWW.BIGDATALEADERSFORUM.COM
The path from Big Data to precision medicine

08.30 CHAIR INTRODUCTION – THE PATH FROM DATA ANALYTICS TO PRECISION MEDICINE
- What are the challenges in combining comprehensive data, collected over time, from genetics, environment and lifestyle, to advance disease understanding and intervention, aid drug discovery and ensure delivery of appropriate therapies?

08.35 [PANEL] THE CHALLENGES OF ADAPTING DRUG DEVELOPMENT AND HEALTHCARE TO THE AGE OF PERSONALIZED THERAPIES
- How are we setting research objectives within biopharma for ‘precision medicine’ and how will new insights translate into advancement for clinical investigations/experimental therapeutics?
- If our vision of precision medicine is to deliver diagnostic tests and to identify responsive patients, alongside new targeted therapies, what pressure will this put on development resources, including the unprecedentedly large volumes of data early in preclinical and clinical testing?
- How can the industry plan to recoup development costs with precision drugs targeting only a subset of a particular patient population? Where is the profitability?

Panelists:
- Dr Rick Dewey, Senior Director, Head of Translational Genetics, Regeneron
- Dr Cecilia Schott, VP, Precision Medicine, Global Product & Portfolio Strategy, Astrazeneca
- Dr Kelly Zou, Senior Director & Analytic Science Lead, Real World Data & Analytics, Pfizer
- Dr Ravinder Dhawan, Vice President & Head of Oncology, Center for Observational & Real World Evidence (CORE), Merck

09.10 [RESERVED] ESTABLISHING THE CAPABILITIES TO VALIDATE AND SECURELY MANAGE LARGE, COMPLEX DATA SETS INVOLVED IN MASSIVE GENOME SEQUENCING PROJECTS

09.25 IDENTIFYING THE FUTURE NEEDS FOR BIG DATA IN MEDICINES REGULATION
- Dr Sean Khoozin, Senior Medical Officer, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, FDA (Invited)

09.40 TRANSFORMING THERAPEUTIC DISCOVERY AND DEVELOPMENT USING AN INTEGRATED OMICS STRATEGY
- Dr Karen Akkinanya, Associate Vice President, Translational Research, Insights & Analytics & Partnering, Merck

09.55 [PANEL] FOSTERING A COLLABORATIVE APPROACH TO EVALUATING –OMICS AND PHENOTYPE DATA
- Encouraging collaboration among industry players and other stakeholders: What is the strategy? What can our resources achieve and how do we need to partner?
- How can partnerships in a diverse range of projects and sharing data across a broad research community, increase our understanding for the mechanisms of disease and potentially accelerate the development of clinically useful markers, targets and therapeutics?
- How can we help to accelerate a broad adoption of clinical data standards and fully realize the vision of semantic interoperability, in order to give us the ability to exchange data rapidly with meaning and actionable insights?

Panelists:
- Dr Marc S. Williams, Director, Genomic Medicine Institute, Geisinger Health System
- Jonathan Chainey, Global Head, Data Standards, PD Biometrics, Roche
- David R. Bobbitt, MSE, MBA, President and CEO, CDISC
- Dr Jane Wilkinson, Senior Director, Genomics Platform Projects & Alliances, Broad Institute
- Dr Victoria Gamerman, Head of Health Informatics & Analytics, Boehringer Ingelheim

10.25 [ROUND TABLE DISCUSSIONS] ESTABLISHING MULTI-STAKEHOLDER DRUG DEVELOPMENT
- The one-company in-house approach of the past has transitioned to a network-driven model that must create closer collaboration between the industry and other parties
- How can we shift our strategy from an application-centric focus to a data-centric focus; where investigators strive to aggregate data from all sources into a centralized repository, giving clinicians access to this knowledge pool with virtually any analytics tool or user interface

Table 1: Dr Jim Ford, Director of Clinical Genomic Strategy, Stanford Cancer Institute

11.25 CHAIR INTRODUCTION

11.30 [PANEL] THE USE OF PUBLIC AND PRIVATE DATABASES TO SUPPORT THE PRACTICE OF GENOMIC MEDICINE
- Is it really acceleration by collaboration? Can innovative partnerships hold great potential for pharma R&D? What is the goal - to look at a subgroup of patients (eg. 10,000) or at each individual?
- The logistical challenges of delivering a large research study - how is it possible to enrol all these patients?
- The scope and role of registries; determining the clinical impact of molecular profiling on disease types

Panelists:
- Dr Daniel Auclair, SVP Research, Multiple Myeloma Research Foundation
- Dr Brad Perkins, Chief Medical Officer, Human Longevity
- Dr Amy Abernethy, Chief Medical Officer, Flatiron Health
- Dr Grant Wood, Clinical Genetics Institute, Intermountain Healthcare

DATA ANALYSIS IN GENE EDITING
- Insight from CRISPR Therapeutics
- Landscape of CRISPR guide sites and their off-targets as well as designing hybrid capture libraries to enrich the genome for off-target edit detection

Dr Andrew Kernshty, Head of Computational Biology, CRISPR Therapeutics

PREDICTIVE MODELING OF HEALTH RISKS AND HEALTH OUTCOMES USING INTEGRATIVE ANALYSES OF CLINICAL, BIOMEDICAL, ENVIRONMENTAL, BEHAVIORAL, AND SOCIO-DEMOGRAPHIC DATA
- Multiple Myeloma Research Foundation
- Dr Vasant G Honavar, Professor and Edward Frymoyer Chair of Information Sciences and Technology, and Professor of Computer Science and of Bioinformatics and Genomics, Director, Artificial Intelligence Research Laboratory, Director, Center for Big Data Analytics and Discovery Informatics, Associate Director, Institute for CyberScience, Pennsylvania State University

ARTIFICIAL INTELLIGENCE TO FURTHER OUR UNDERSTANDING OF DENGUE DISEASE AND VACCINATION MECHANISMS
- Dr Dany DeGrave, Senior Director Innovation Programs & External Networks, Sanofi

[RESERVED]: WHAT COULD ARTIFICIAL INTELLIGENCE MEAN FOR PHARMA?

[PANEL] ARTIFICIAL INTELLIGENCE: ACHIEVING PRECISION MEDICINE AT SCALE
- Methods to integrate clinical, molecular, and real world data at large scales to build tremendous cloud-based holistic models for stimulation experiments and investigation into disease
- Managing and deriving value from quantitative patient data to understand patient sub-populations, identify biomarkers of disease onset, progression, or patient stratification, assess clinical risk, and uncover mechanistic understanding of disease
- By applying unsupervised deep learning to massive data we expect to identify new biomarkers and precise phenotypes that can serve as the foundation for building personalized diagnostic and treatment pathways

Panelists: speakers of the session plus:
- Dr Andrew Swick, SVP Product Development & Scientific Affairs, Life Extension
**Transforming datasets into actionable information**

14.30 **CHAIR INTRODUCTION**

14.35 **TRANSFORMING THERAPEUTIC DISCOVERY AND DEVELOPMENT USING AN INTEGRATED GENOMICS STRATEGY**

Dr Rick Dewey, Senior Director, Head of Translational Genetics, Regeneron

14.50 **HIGH DEFINITION MEDICINE: A VISION FOR THE UTILITY OF PERSONAL HEALTH DATA**

Dr Ali Torkamani, Director of Genome Informatics & Drug Discovery, The Scripps Translational Science Institute

15.05 [RESERVED] IDENTIFYING DISEASE BIOMARKERS FROM MULTI-OMIC DATA AND CLINICAL OBSERVATIONS.

15.20 [PANEL] TRANSFORMING DATASETS INTO ACTIONABLE INFORMATION

- Seeking new models to connect expanding sets of disparate, non-identified patient-level data streams to better develop and commercialize next-generation medicines
- The need for practical, evidence-based approaches: improving study design by better linking indications and target endpoints; better patient stratification using better inclusion/exclusion criteria and biomarker-based segmentation approaches; using outcomes analysis to determine optimal care paths; evaluating medical value and real-world evidence in decision-making

**How is precision medicine initiatives changing drug development?**

16.10 **CHAIR INTRODUCTION**

16.15 **USING A PRECISION MEDICINE STRATEGY TO OVERHAUL THE ENTIRE BUSINESS MODEL**

- How clinical and real-world evidence can show the efficacy of a given treatment and demonstrate it as a cost-effective and long-term treatment option
- Using a precision medicine strategy to understand where we can overhaul the entire business model across the lifecycle and identify trends and opportunities, even before approaching payers and regulators

Dr Hui Cao, Executive Director, CoE for RWE, Novartis

16.30 [PHARMA ROUNDTABLES] SETTING RESEARCH OBJECTIVES WITHIN BIOPHARMA FOR ‘PRECISION MEDICINE’

- Using a precision medicine strategy, how can we overhaul the entire business model across the lifecycle and identify trends and opportunities, even before approaching payers and regulators
- Advancing a ‘Smart’ Data first strategy: If our vision of precision medicine is to deliver diagnostic tests, to identify responsive patients, alongside new targeted therapies, what pressure will this put on development resources, including the unprecedentedly large volumes of data early in preclinical and clinical testing?

**Table 1: Utilizing data to better identify new drug candidates and/or treatment indications**

| Table 2: Identifying disease biomarkers from multi-omic data and clinical observations |
| Table 3: Text mining and language processing for precision medicine |

17.00 [PANEL] TRANSLATING GENOMIC INFORMATION INTO CLINICAL MEDICINE

Dr Jean C. ZenKluesen, Director, The Cancer Genome Atlas, National Cancer Institute, National Institutes of Health

Dr Sandy Farmer, Executive Director, Genome Sciences & Technologies, Pfizer

Dr Nicholas Marko, Director of Neurosurgical Oncology, Geisinger Health

17.30 CLOSE OF DAY 1 CONFERENCE SESSIONS - DRINKS RECEPTION IN THE EXHIBITION AREA

**How is precision medicine initiatives changing the delivery of healthcare?**

16.10 **CHAIR INTRODUCTION**

16.15 **MEDICAL EDUCATION, BIOMEDICAL RESEARCH AND EXCELLENCE IN PATIENT CARE**

Patrick Farrell, Senior Director, Data Analytics, Penn Medicine

16.30 [PANEL] WHAT TECHNOLOGY CENTERS ARE DOING TO EMBRACE PRECISION MEDICINE

- Setting objectives in precision medicine – how have initiatives changed with the recent development of large-scale biologic databases, new methods to characterize patients and computational tools for analysing large sets of data
- Beyond hype cycle: What experiments are being done in health systems which are affecting clinical care? What are the near-term focuses (cancers?) and longer-term aims in generating knowledge applicable to the whole range of health and disease?

Joseph Dudas, Divisional Chair, Enterprise Analytics, Mayo Clinic

Jeff Waldron, Executive Directors, PM Connective

Dr Paul Nagy, Deputy Director, Johns Hopkins Medicine Technology Innovation Centre. Johns Hopkins University School of Medicine

Mike Restuccia, SVP CIO, Penn Medicine

Dr Teresa Zayas Caban, Head Scientist, Acting Chief of Staff, Office of the National Coordinator for Health Information Technology, US Department of Health and Human Services

17.00 [HEALTHCARE ROUNDTABLE] REALIZING THE POTENTIAL OF PRECISION MEDICINE IN HEALTHCARE

- Creating opportunity through new data architecture
- Increasing value and engagement with healthcare analytics
- Overcoming the significant challenges for the broad implementation of precision medicine in healthcare: insufficient evidence generation, data sharing and infrastructure challenges, slow uptake of genomic information into clinical care and research, the economics, and achieving greater patient and clinician engagement and trust

17.30 CLOSE OF DAY 1 CONFERENCE SESSIONS - DRINKS RECEPTION IN THE EXHIBITION AREA
**Big Data and the promise of precision medicine in cancer**

**11:30** CHAIR INTRODUCTION

**11:35** STANDARDIZED DATA MODEL FOR ONCOLOGY ANALYTICS

Ari Caroline, Chief Analytics Officer, Memorial Sloan Kettering Cancer Center

**11:50** CROSS-PROGRAM EXPLORATION OF CLINICAL DATA ACROSS THE IMMUNO-ONCOLOGY PORTFOLIO USING DATA LAKES AND VISUALIZATIONS

Philip Ross, Director of Clinical Translational Data Science, Bristol Myers Squibb

**12:05** [RESERVED] GENOMIC TECHNOLOGIES AND PHENOTYPE DATA TO STRATIFY PATIENT POPULATIONS IN CLINICAL TRIALS

**12:20** A PLATFORM FOR PERSONALIZED THERAPY IN MYELOMA

Dr Kenneth Shain, Scientific Director, Moffitt Myeloma Working Group, Moffitt Cancer Center

**12:35** [PANEL] PREDICT DRUG RESPONSES IN CANCER RESEARCH

Panellists: Speakers of the session

**Precision medicine for managing chronic diseases**

**11:30** CHAIR INTRODUCTION

**11:35** HOW PERSONALIZED DATA CAN MAXIMIZE THE EFFECT OF CHRONIC DISEASE TREATMENT

- Correlating genomic insights with environmental, behavioural and medical factors to have a more holistic view of disease

Dr Iris Grossman, VP, Head of Personalized & Predictive Medicine, Teva Pharmaceuticals

[CASE STUDIES] PRECISION MEDICINE STRATEGIES IN CHRONIC AIRWAY DISEASES, DIABETES AND CARDIOVASCULAR DISEASE

**11:50** CASE STUDY 1

Dr Chengming Gu, Vice President, Medical Affairs, Pfizer China

**12:10** CASE STUDY 2 RESERVED

**12:30** [PANEL] PAVING THE WAY FOR SYSTEMS BIOLOGY AND PRECISION MEDICINE IN MULTIPLE DISEASE AREAS

- How do we get from real world datasets to cell biology?
- Precision insights have the ability to identify distinct patient subgroups, non-genomic mechanisms of disease initiation and progression - who to target?

Panellists: Speakers of the session plus

Dr Hui Cao, Executive Director, CoE for RWE, Novartis

**Applying precision medicine in neuroscience**

**14:10** CHAIR INTRODUCTION

**14:15** IMMUNE-DEMENIA: HUMAN GENETICS-GUIDED DRUG DISCOVERY FOR ALZHEIMER’S DISEASE

Dr Akihiko Koyama, Head, Integrated Biology Engine, Andoover innovative Medicine Institute

**14:30** PRESENTATION RESERVED

**14:45** TOWARDS PRECISION MEDICINE IN PSYCHIATRY: BRIDGING THE GAP FROM BIG DATA TO BIG INSIGHTS

Dr Gayle Wittenberg, Head, Translational Research & Precision Medicine, Pharma R&D IT, Director, Integrative Solutions & Informatics, Neuroscience, Janssen Research & Development

**15:00** [PANEL] ACCELERATE TRANSLATIONAL AND CLINICAL RESEARCH IN NEUROLOGICAL DISORDERS THROUGH ASSESSING DATA OF NOVEL THERAPIES

- Bringing efficiency strategies and infrastructure to clinical research
- Establishing and managing disease-specific research consortia
- Custom design of clinical research protocols

Panellists, speakers of the session plus:

Dr Alex Sherman, Director, Strategic Development & Systems, Neurological Clinical Research Institute, Massachusetts General Hospital

**15:25** DATA-DRIVEN INTEROPERABILITY

- Accelerating the impact of research information exchange
- Maximizing existing research data storage and empowering discovery teams

Dr Philip Payne, Chief Scientific Officer, Signet Accel

**16:05** [RESERVED] USING BIG DATA TO UNDERSTAND RARE DISEASES

**16:25** INTEGRATED GENOMIC ADVANCES AND ITS IMPACT ON CLINICAL TRIAL DESIGN AND DELIVERY

- Supporting GSK drug assets by using genetic biomarkers to help predict efficacy and better understand adverse events

Dr Charles Cox, Head of Pharmacogenetics, GSK

**16:45** MOVING TOWARDS GENOMICS DRIVEN PRECISION MEDICINE IN ASIA

**17:00** CLOSE OF CONFERENCE
SPEAKERS ALREADY CONFIRMED INCLUDE:

Dr Cecilia Schott  
VP Precision Medicine, Global Product & Portfolio  
AstraZeneca

Dr Jean-Claude Zenklusen  
Director, Cancer Genome Atlas  
NCI

Dr Brad Perkins  
Chief Medical Officer  
Human Longevity

Dr Anthony Kerlavage  
Acting Director, Center for Biomedical Informatics and IT  
National Cancer Institute

Dr Ray Liu  
Senior Director & Head, Advanced Analytics & Statistical Innovation  
Intermountain Healthcare

Dr Grant Wood  
Clinical Genetics Institute  
Takeda Pharmaceuticals

Dr Daniel Aucott  
Senior Director & Head, Advanced Genomics  
Geisinger Health System

Dr Paul Nagy  
Director, John Hopkins Medicine Technology  
John Hopkins University School of Medicine

Dr James Ford  
Director of Clinical Cancer Genomics  
Stanford Cancer Institute

Dr Rick Dewey  
Senior Director, Head of Translational Genetics  
Regeneron

Dr Andrew Johnson  
Head, Biomedical Informatics, Population Science Branch  
NHGRI

Dr Marc-S. Williams  
Director, Genomic Medicine Institute  
Geisinger Health System

David Bobbitt  
President and CEO  
CDISC

Cathy Marshall  
Director, Clinical Data Sciences  
Pfizer

Dr James O'Leary  
Chief Innovation Officer  
Genetic Alliance

Dr Jane Wilkinson  
Senior Director, Genomics Platform Projects & Alliances  
Broad Institute

Dr Elise Berliner  
Director, Technology Assessment Program, Center for Evidence and Practice Improvement  
AHRQ

Dr Kenneth Shain  
Scientific Director, Moffitt Myeloma Working Group  
Moffitt Cancer Center

Jonathan Chaine  
Global Head, Data Standards, PD BIometrics  
Roche

Dr Shuvayu Sen  
Executive Director, Outcomes Research & Access  
Merck

Dr Joseph Dudus  
Division Chair, Enterprise Analytics  
Mayo Clinic

Dr Alex Sherman  
Director, Strategic Development & Systems, Neurological Clinical Research Institute  
Massachusetts General Hospital

Dr Iris Grossman  
VP, Head of Personalized & Predictive Medicine  
Teva Pharmaceuticals

Dr Ali Torkamani  
Director of Genome Informatics & Drug Discovery  
The Scripps Translational Science Institute

Dr Sandy Farmer  
Executive Director, Enterprise Scientific Technology Operations  
Pfizer

Dr Hui Cao  
Executive Director, CoE for RWE  
Novartis

Dr Balazs Flink  
Head of Clinical Trial Analysis  
Bristol-Myers Squibb

Mike Restuccia  
SVP CIO  
University of Pennsylvania Health System

Leo Barella  
Chief Enterprise Architect  
AstraZeneca

Dr Rick Dewey  
Senior Director, Head of Translational Genetics  
Regeneron

Dr Philip Ross  
Director of Clinical Translational Data Science  
Bristol Myers Squibb

Dr Ari Caroline  
Chief Analytics Officer  
Memorial Sloan Kettering Cancer Center

Dr Kelly Zou  
Senior Director & Analytical Science Lead  
Pfizer

Jeff Waldron  
Executive Director  
PM Connective

Dr Andrew Swick  
SVP Product Development & Scientific Affairs  
Life Extension

Dr Charles Cox  
Head of Pharmacogenetics  
OSK

Dr Victoria Gamez  
Head of Health Informatics & Analytics  
Boehringer Ingelheim

Patrick Farrell  
Senior Director, Data Analytics, Penn Medicine  
M2Gen

Dr William Dalton  
CEO, M2Gen

Dr Karen Akinsanya  
Associate VP Translational Research, Insights & Partnering  
Merck

Dr Ravinder Dhawan  
Vice President & Head of Oncology, Center for Observational and Real-World Evidence (CORE)  
Merck

Dr Michael Boedigheimer  
Director, Computational Biology, Medical Sciences  
Amgen

Dr Dany DeGrave  
Senior Director Innovation Programs & External Networks  
Sanofi

Dr Chengming Gu  
Vice President, Medical Affairs  
Pfizer

Dr Gayle Wittenberg  
Head Translational Research & Precision Medicine  
Janssen Research and Development, LLC

Dr Itfikhar Kullo  
Principal Investigator, Cardiovascular Disease, College of Medicine  
Mayo Clinic

Dr Philip Payne  
Chief Scientific Officer  
Signet Accel

Dr Nicholas Marko  
Director of Neurosurgical Oncology  
Geisinger Health

Dr Olivier Luttringer  
Global Head, Modeling and Simulation, Real World Evidence  
Novartis

Dr Amy Abernethy  
Chief Medical Officer  
Flatiron Health

Dr Akikiko Koyama  
Head of Integrated Biology Engine  
Eisai

Dr Teresa Zayas Caban  
Chief Scientist, Acting Chief of Staff, Office of the National Coordinator for Health Information Technology  
US Department of Health and Human Services

Dr Andrew Kerkutsky  
Head of Computational Biology  
CRISPR Therapeutics

Dr. Akikiko Koyama  
Head, Integrated Biology Engine  
Andover Innovative Medicine Institute

Dr Vasant G Honavar  
Professor, Computer Science, Bioinformatics and Genomics, and Neuroscience Graduate Programs  
Director, Artificial Intelligence Research Laboratory, Director, Center for Big Data Analytics and Discovery Informatics, Associate Director, Institute for CyberScience  
College of Information Sciences and Technology

Christian Schubert  
Director, Business Development & External Innovation  
Biogen

Dr Sean Khozim  
Senior Medical Officer, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research  
FDA (Invited)

More speakers are being confirmed all the time, to see the latest list visit www.bigdataleadersforum.com now!

WANT TO JOIN THIS STELLAR PANEL?  
There are still speaking opportunities available - contact Peter Harkness now on peter.harkness@phacilitate.co.uk or on +44(0)20 7384 8027
“Great and enthusiastic mix of people responsible for planning and doing, creating value, solving problems, serving patients."

Mr Jeff Gallagher, CEO, Virginia Bio

“Great event, right sized to be able to have direct, constructive interaction with national leaders from government, academia, and industry.”

Mr Morgan Crafts, Deputy Director, Tech, Life Science, Northrop Grumman

Previous sponsors include:

BOOK YOUR CONFERENCE PASS NOW TO SAVE $$ $$ s!

<table>
<thead>
<tr>
<th>EARLY BIRD</th>
<th>STANDARD RATES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Until Friday 15 September 2017</td>
<td></td>
</tr>
<tr>
<td>Delegate Type</td>
<td>Delegate Type</td>
</tr>
<tr>
<td>Pharma/Biotech/CRO</td>
<td>Pharma/Biotech/CRO</td>
</tr>
<tr>
<td>Academic/Govt/Not-for-Profit</td>
<td>Academic/Govt/Not-for-Profit</td>
</tr>
<tr>
<td>Technology/Service Provider</td>
<td>Technology/Service Provider</td>
</tr>
<tr>
<td>Rates $1,795</td>
<td>Rates $1,995</td>
</tr>
<tr>
<td>Rates $895</td>
<td>Rates $995</td>
</tr>
<tr>
<td>Rates $2,995</td>
<td>Rates $2,995</td>
</tr>
</tbody>
</table>

FOR INFORMATION ON:
Small company rates • Group discounts • 1 day attendance
Contact Phacilitate now on team@phacilitate.co.uk or call +44 (0)20 7384 7993

JOIN THE CONVERSATION AT WWW.BIGDATALEADERSFORUM.COM